(Total Views: 248)
Posted On: 03/29/2019 6:43:10 AM
Post# of 72436
second is *imo* most with functioning gray matter could understand today's news
I liked the whole post but wanted to highlight the above part.
First of all, I know that we know there is a process of moving a drug through to start any trial. I also know that they know when that process is nearing a critical catalyst.
That catalyst is announcing the protocol and funding to make it happen.
I think we're pretty split on when that'll be announced. Before or after the mid April meeting. I think it would be prudent to get it all on the street before the meeting but really, it doesn't matter as long as it gets done. And soon. From the news they clearly already have a protocol.
In December, Innovation Pharmaceuticals completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), during which an acceptable Phase 3 development pathway was agreed upon to advance Brilacidin.
EMA advice is integral to this plan by helping to ensure that the program meets European standards.
For the Phase 3 program, the Company anticipates international clinical trial enrollment, with participating sites located in the U.S. and in Europe.
Now we just need Leo & Dr. B to show us the money!
Any day now. Within about 12-18 days.
Mr. Obvious
They know who they are. And when the money hits the street, they're toast.
I liked the whole post but wanted to highlight the above part.
First of all, I know that we know there is a process of moving a drug through to start any trial. I also know that they know when that process is nearing a critical catalyst.
That catalyst is announcing the protocol and funding to make it happen.
I think we're pretty split on when that'll be announced. Before or after the mid April meeting. I think it would be prudent to get it all on the street before the meeting but really, it doesn't matter as long as it gets done. And soon. From the news they clearly already have a protocol.
In December, Innovation Pharmaceuticals completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), during which an acceptable Phase 3 development pathway was agreed upon to advance Brilacidin.
EMA advice is integral to this plan by helping to ensure that the program meets European standards.
For the Phase 3 program, the Company anticipates international clinical trial enrollment, with participating sites located in the U.S. and in Europe.
Now we just need Leo & Dr. B to show us the money!
Any day now. Within about 12-18 days.
Mr. Obvious
Quote:
but 4 things stand out today .. (5th will be what DRS shows me)
first is news came out pre mkt .. which allowed CSTI to then UC the ask and block via their UC ask b4 mkt opened (i'll break out those blocks on today's tape of trades)
second is *imo* most with functioning gray matter could understand today's news
remember my adage .. *if able to* a significantly upside down NR has to make good news look bad (close down on volume) .. and bad news look fatal (significant close down on significant volume) .. IPIX closing green on lower volume did not work in NRs' favor today
third .. NR could not do volume maintenance on IPIX (NR has issues) .. tho' they came close to 10 day vol algos .. close doesn't cut it
fourth .. very rough count on hidden trades today (25000 - 30000) .. % approx 10% .. below what has been done *recently*
IPIX Volume 286,544
Volume (10 day Average) 291,618
Volume (90 day Average) 480,693
be interesting to see what tomorrow brings once there is a little digestion of today's news ..
4kids
They know who they are. And when the money hits the street, they're toast.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)